Get started
Author

Catherine Dopchie

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012 · E. Seront, S. Rottey, et al. · Annals of Oncology · 129
PDF
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
2008 · Jean-Pascal Machiels, Filomena Mazzeo, et al. · Journal of Clinical Oncology · 87
PDF
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study
2019 · Martin Boegemann, Sara Khaksar, et al. · BMC Cancer · 45
PDF
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
2020 · Sandro Pignata, Giovanni Scambia, et al. · The Oncologist · 21
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
2019 · Christel Fontaine, Vincent Renard, et al. · Breast Cancer Research and Treatment · 14
Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.
2009 · H. Roché, D. Allouache, et al. · Cancer Research · 14
Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
2007 · J. H. Machiels, F. Mazzeo, et al. · Journal of Clinical Oncology · 5
Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study
2021 · Lionel Duck, Gauthier Demolin, et al. · Clinical Therapeutics · 4
[Gallbladder metastasis from breast carcinoma: a new case report].
2012 · B Essola, P Malvaux, et al. · PubMed · 4
The Doctor Turned into an Instrument
2021 · Catherine Dopchie · Springer eBooks · 3
PDF
Hematology, palliative care, and human sciences: a dialogue that changes portrayals
2017 · Chloé Prod’homme, Nathalie Cambier, et al. · Hématologie · 3
Accueillir la vulnérabilité
2020 · Catherine Dopchie · Érès eBooks · 2
Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
2017 · Martin Boegemann, Martin Hatzinger, et al. · Journal of Clinical Oncology · 2
Heterozygote Germline Mutations in Homologous Recombination Core Genes Can Predict for Pathologic Complete Response in Early Triple Negative Breast Cancer
2023 · Christel Fontaine, Sylvia De Brakeleer, et al. · Journal of Biotechnology and Biomedicine · 1
Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO): Results from a phase II multicenter study.
2019 · Lionel Duck, Gauthier Demolin, et al. · Journal of Clinical Oncology · 1
L'euthanasie tue-t-elle les soins palliatifs?
2024 · Dopchie, Catherine · Cahiers francophones de soins palliatifs
Abstract P1-10-05: Evaluation of germline whole exome sequencing of early breast cancer patients with triple negative breast cancer (TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)
2020 · Christel Fontaine, Vincent Renard, et al. · Cancer Research
P118 European, non-interventional, phase IV NIMES-ROC trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive recurrent ovarian cancer: an interim analysis
2019 · L.M. de Sande González, G. Scambia, et al. · International Journal of Gynecological Cancer
Abstract P2-08-47: Evaluation of stromal tumor-infiltrating lymphocytes (sTIL) and tertiary lymphoid structures (TLS) in early breast cancer patients with triple negative breast cancer(TNBC) included in a prospective study of neoadjuvant chemotherapy (NAC) with Epirubicin and cyclophosphamide (EC) and carboplatin-paclitaxel (PC) (BSMO 2014-01)
2019 · C Fontaine, G Van den Eynden, et al. · Cancer Research
Abstract P6-15-09: Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study
2018 · C Fontaine, N Cappoen, et al. · Cancer Research
Accompagner la fragilité de la fin de vie
2017 · Catherine Dopchie · Presses de l'Université Laval eBooks
Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology
2017 · C Fontaine, N Cappoen, et al. · Cancer Research
Abstract P6-11-08: A Comparison of Chemotherapeutic Treatment Practice in Metastatic Breast Cancer (MBC) in Belgium (BE) and The Netherlands (NL)
2010 · E de Jongh, D van Brummelen, et al. · Cancer Research
A Retrospective Survey of Systemic Anticancer Therapy in Women With Metastatic Breast Cancer (mbc) in Belgium
2010 · Fontaine, C., JANSSENS, Jaak, et al. · Document Server@UHasselt (UHasselt)
Works count: 27
Citation count: 337
H-index: 6
I10-index: 6
Year
Topic
Type